[Effectiveness and characteristics of the action of etmozin in treating extrasystole in middle-aged and elderly patients].
Antiarrhythmic efficiency and specific effects of ethmozine, taken alone in increasing oral doses from 300 to 450 mg daily, were evaluated in 48 elderly and old coronary patients with stable supraventricular and ventricular extrasystoles (SVES, VES). It was demonstrated clinically and instrumentally (ECG, rhythmography, bicycle ergometry with standard exercise, cardiac rhythm monitoring and computer analysis, polycardiography, tetrapolar chest rheography) that ethmozine's antiarrhythmic effect was marked (a more than 75% post-treatment decline in the frequency of extrasystoles at rest and during exercise, provided that paired polytopic extrasystoles and paroxysms of tachycardia are suppressed completely) in 52.1% of SVES patients and 60% of VES patients. Antiarrhythmic action of a 300 mg ethmozine load dose was particularly apparent within 2-7 hours after administration. Ethmozine treatment, as described above, delayed atrioventricular conduction, causing however no significant decrease in heart rate, nor depressing cardiac output and myocardial function; arterial blood pressure and myocardial oxygen requirement remained basically unchanged either. Unlike propranolol effect on cardiac rhythm undulating pattern, there is evidence that ethmozine mechanism of action involves sympathetic activation. Ethmozine had to be discontinued in 10.4% of the 35.4% of patients with side effects.